Last Updated: November 9, 2026

CLINICAL TRIALS PROFILE FOR LITHOBID

« Back to Dashboard

All Clinical Trials for LITHOBID

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00183443 ↗	Treatment of Mania Symptoms With Drug Therapy	Completed	National Institute of Mental Health (NIMH)	Phase 3	2005-02-01	This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
NCT00183443 ↗	Treatment of Mania Symptoms With Drug Therapy	Completed	Palo Alto Veterans Institute for Research	Phase 3	2005-02-01	This study will determine the effectiveness of three different drug therapies in treating the symptoms of mania.
NCT00408681 ↗	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Completed	National Cancer Institute (NCI)	N/A	2006-06-01	RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.
NCT00408681 ↗	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Completed	Fred Hutchinson Cancer Research Center	N/A	2006-06-01	RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.
NCT00601536 ↗	Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions	Completed	Roxane Laboratories	N/A	2003-04-01	The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fasting conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.
NCT00602394 ↗	Bioequivalency Study of 300 mg Lithium Carbonate Under Fed Conditions	Completed	Roxane Laboratories	N/A	2003-05-01	The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release tablet under fed conditions using a single-dose, randomized, 2 treatment, 2-period, 2-sequence crossover design.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for LITHOBID

Condition Name

Chart
Table

Condition Name for LITHOBID
Intervention	Trials
Bipolar Disorder	4
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)	2
Recurrent Adult Acute Myeloid Leukemia	2
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for LITHOBID
Intervention	Trials
Bipolar Disorder	5
Depressive Disorder	3
Depression	3
Leukemia, Myeloid, Acute	2
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for LITHOBID

Trials by Country

Map
Table

Trials by Country for LITHOBID
Location	Trials
United States	19
Sweden	2
Norway	1
China	1
Canada	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for LITHOBID
Location	Trials
Ohio	2
New York	2
Michigan	2
Texas	2
Pennsylvania	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for LITHOBID

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for LITHOBID
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for LITHOBID
Clinical Trial Phase	Trials
Completed	9
Recruiting	2
Terminated	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LITHOBID

Sponsor Name

Chart
Table

Sponsor Name for LITHOBID
Sponsor	Trials
National Institute of Mental Health (NIMH)	3
National Cancer Institute (NCI)	2
Columbia University	2
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for LITHOBID
Sponsor	Trials
Other	24
NIH	6
Industry	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.